<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p113" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_113{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#t2_113{left:285px;bottom:827px;letter-spacing:-0.27px;}
#t3_113{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t4_113{left:341px;bottom:30px;}
#t5_113{left:348px;bottom:25px;letter-spacing:0.11px;}
#t6_113{left:377px;bottom:30px;}
#t7_113{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t8_113{left:540px;bottom:30px;}
#t9_113{left:546px;bottom:25px;letter-spacing:0.07px;}
#ta_113{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#tb_113{left:44px;bottom:63px;letter-spacing:0.1px;}
#tc_113{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_113{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_113{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_113{left:1111px;bottom:47px;letter-spacing:0.18px;}
#tg_113{left:1121px;bottom:28px;letter-spacing:0.19px;word-spacing:-0.15px;}
#th_113{left:1083px;bottom:83px;letter-spacing:-0.1px;}
#ti_113{left:42px;bottom:682px;letter-spacing:-0.09px;}
#tj_113{left:42px;bottom:658px;letter-spacing:-0.1px;}
#tk_113{left:402px;bottom:658px;letter-spacing:-0.11px;}
#tl_113{left:402px;bottom:640px;letter-spacing:-0.09px;}
#tm_113{left:807px;bottom:658px;letter-spacing:-0.09px;}
#tn_113{left:807px;bottom:640px;letter-spacing:-0.09px;}
#to_113{left:42px;bottom:615px;letter-spacing:-0.09px;}
#tp_113{left:118px;bottom:623px;}
#tq_113{left:42px;bottom:597px;}
#tr_113{left:52px;bottom:597px;letter-spacing:-0.09px;}
#ts_113{left:53px;bottom:578px;letter-spacing:-0.09px;}
#tt_113{left:186px;bottom:578px;letter-spacing:-0.09px;}
#tu_113{left:276px;bottom:586px;letter-spacing:-0.12px;}
#tv_113{left:42px;bottom:560px;}
#tw_113{left:52px;bottom:560px;letter-spacing:-0.09px;}
#tx_113{left:53px;bottom:542px;letter-spacing:-0.1px;}
#ty_113{left:267px;bottom:549px;letter-spacing:-0.09px;}
#tz_113{left:296px;bottom:542px;letter-spacing:-0.08px;word-spacing:0.01px;}
#t10_113{left:42px;bottom:510px;letter-spacing:-0.09px;}
#t11_113{left:42px;bottom:491px;letter-spacing:-0.09px;}
#t12_113{left:132px;bottom:499px;letter-spacing:-0.09px;}
#t13_113{left:151px;bottom:491px;letter-spacing:-0.08px;}
#t14_113{left:53px;bottom:473px;letter-spacing:-0.08px;}
#t15_113{left:42px;bottom:455px;}
#t16_113{left:52px;bottom:455px;letter-spacing:-0.1px;}
#t17_113{left:169px;bottom:462px;letter-spacing:-0.11px;}
#t18_113{left:208px;bottom:455px;letter-spacing:-0.08px;}
#t19_113{left:53px;bottom:436px;letter-spacing:-0.08px;}
#t1a_113{left:402px;bottom:615px;letter-spacing:-0.11px;}
#t1b_113{left:402px;bottom:597px;letter-spacing:-0.08px;}
#t1c_113{left:413px;bottom:578px;letter-spacing:-0.09px;}
#t1d_113{left:543px;bottom:586px;letter-spacing:-0.14px;}
#t1e_113{left:563px;bottom:578px;letter-spacing:-0.09px;}
#t1f_113{left:402px;bottom:560px;letter-spacing:-0.09px;}
#t1g_113{left:558px;bottom:568px;letter-spacing:-0.14px;}
#t1h_113{left:402px;bottom:542px;letter-spacing:-0.08px;}
#t1i_113{left:660px;bottom:549px;letter-spacing:-0.14px;}
#t1j_113{left:680px;bottom:542px;letter-spacing:-0.08px;}
#t1k_113{left:770px;bottom:549px;letter-spacing:-0.14px;}
#t1l_113{left:402px;bottom:523px;letter-spacing:-0.08px;}
#t1m_113{left:519px;bottom:531px;letter-spacing:-0.13px;}
#t1n_113{left:402px;bottom:505px;letter-spacing:-0.09px;}
#t1o_113{left:742px;bottom:513px;letter-spacing:-0.09px;}
#t1p_113{left:402px;bottom:487px;letter-spacing:-0.08px;}
#t1q_113{left:740px;bottom:494px;letter-spacing:-0.14px;}
#t1r_113{left:402px;bottom:468px;}
#t1s_113{left:413px;bottom:468px;letter-spacing:-0.09px;}
#t1t_113{left:413px;bottom:450px;letter-spacing:-0.09px;}
#t1u_113{left:485px;bottom:458px;letter-spacing:-0.13px;}
#t1v_113{left:402px;bottom:432px;}
#t1w_113{left:413px;bottom:432px;letter-spacing:-0.09px;}
#t1x_113{left:413px;bottom:413px;letter-spacing:-0.08px;}
#t1y_113{left:483px;bottom:421px;letter-spacing:-0.12px;}
#t1z_113{left:402px;bottom:377px;letter-spacing:-0.1px;word-spacing:-0.64px;}
#t20_113{left:402px;bottom:358px;letter-spacing:-0.08px;}
#t21_113{left:477px;bottom:366px;letter-spacing:-0.13px;}
#t22_113{left:402px;bottom:340px;letter-spacing:-0.09px;}
#t23_113{left:499px;bottom:348px;letter-spacing:-0.14px;}
#t24_113{left:402px;bottom:322px;letter-spacing:-0.08px;}
#t25_113{left:485px;bottom:329px;letter-spacing:-0.14px;}
#t26_113{left:402px;bottom:303px;letter-spacing:-0.09px;}
#t27_113{left:487px;bottom:311px;letter-spacing:-0.13px;}
#t28_113{left:402px;bottom:285px;letter-spacing:-0.09px;}
#t29_113{left:450px;bottom:293px;letter-spacing:-0.14px;}
#t2a_113{left:402px;bottom:267px;letter-spacing:-0.09px;}
#t2b_113{left:511px;bottom:274px;letter-spacing:-0.13px;}
#t2c_113{left:402px;bottom:248px;letter-spacing:-0.1px;}
#t2d_113{left:493px;bottom:256px;letter-spacing:-0.13px;}
#t2e_113{left:402px;bottom:230px;letter-spacing:-0.09px;}
#t2f_113{left:511px;bottom:238px;letter-spacing:-0.14px;}
#t2g_113{left:402px;bottom:212px;letter-spacing:-0.08px;}
#t2h_113{left:469px;bottom:219px;letter-spacing:-0.14px;}
#t2i_113{left:484px;bottom:212px;letter-spacing:-0.12px;word-spacing:0.04px;}
#t2j_113{left:413px;bottom:193px;letter-spacing:-0.08px;}
#t2k_113{left:413px;bottom:175px;letter-spacing:-0.09px;}
#t2l_113{left:807px;bottom:615px;letter-spacing:-0.09px;}
#t2m_113{left:812px;bottom:597px;}
#t2n_113{left:829px;bottom:597px;letter-spacing:-0.1px;}
#t2o_113{left:990px;bottom:604px;letter-spacing:-0.14px;}
#t2p_113{left:812px;bottom:578px;}
#t2q_113{left:829px;bottom:578px;letter-spacing:-0.1px;}
#t2r_113{left:1029px;bottom:586px;letter-spacing:-0.14px;}
#t2s_113{left:807px;bottom:560px;letter-spacing:-0.08px;}
#t2t_113{left:818px;bottom:542px;letter-spacing:-0.08px;}
#t2u_113{left:818px;bottom:523px;letter-spacing:-0.09px;}
#t2v_113{left:818px;bottom:505px;letter-spacing:-0.09px;}
#t2w_113{left:812px;bottom:487px;}
#t2x_113{left:829px;bottom:487px;letter-spacing:-0.08px;}
#t2y_113{left:829px;bottom:468px;letter-spacing:-0.09px;}
#t2z_113{left:901px;bottom:476px;letter-spacing:-0.14px;}
#t30_113{left:812px;bottom:450px;}
#t31_113{left:829px;bottom:450px;letter-spacing:-0.09px;}
#t32_113{left:829px;bottom:432px;letter-spacing:-0.08px;}
#t33_113{left:1009px;bottom:439px;letter-spacing:-0.14px;}
#t34_113{left:807px;bottom:413px;letter-spacing:-0.09px;}
#t35_113{left:970px;bottom:421px;letter-spacing:-0.14px;}
#t36_113{left:807px;bottom:395px;letter-spacing:-0.09px;}
#t37_113{left:1079px;bottom:403px;letter-spacing:-0.14px;}
#t38_113{left:807px;bottom:377px;}
#t39_113{left:817px;bottom:377px;letter-spacing:-0.1px;word-spacing:-0.06px;}
#t3a_113{left:818px;bottom:358px;letter-spacing:-0.09px;}
#t3b_113{left:977px;bottom:366px;letter-spacing:-0.14px;}
#t3c_113{left:807px;bottom:340px;letter-spacing:-0.09px;}
#t3d_113{left:818px;bottom:322px;letter-spacing:-0.1px;}
#t3e_113{left:844px;bottom:329px;letter-spacing:-0.14px;}
#t3f_113{left:807px;bottom:303px;letter-spacing:-0.09px;}
#t3g_113{left:1092px;bottom:311px;letter-spacing:-0.14px;}
#t3h_113{left:807px;bottom:285px;}
#t3i_113{left:817px;bottom:285px;letter-spacing:-0.09px;}
#t3j_113{left:818px;bottom:267px;letter-spacing:-0.09px;}
#t3k_113{left:960px;bottom:274px;letter-spacing:-0.14px;}
#t3l_113{left:807px;bottom:248px;}
#t3m_113{left:817px;bottom:248px;letter-spacing:-0.09px;}
#t3n_113{left:818px;bottom:230px;letter-spacing:-0.09px;}
#t3o_113{left:818px;bottom:212px;letter-spacing:-0.08px;}
#t3p_113{left:818px;bottom:193px;letter-spacing:-0.09px;}
#t3q_113{left:1059px;bottom:201px;letter-spacing:-0.14px;}
#t3r_113{left:42px;bottom:716px;letter-spacing:-0.09px;}
#t3s_113{left:35px;bottom:114px;}
#t3t_113{left:45px;bottom:108px;letter-spacing:0.13px;}
#t3u_113{left:267px;bottom:778px;letter-spacing:0.39px;word-spacing:-0.23px;}
#t3v_113{left:60px;bottom:760px;letter-spacing:-0.09px;}
#t3w_113{left:543px;bottom:742px;letter-spacing:-0.1px;}
#t3x_113{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_113{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s1_113{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s2_113{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s3_113{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_113{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_113{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_113{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.s7_113{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.s8_113{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.s9_113{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.sa_113{font-size:17px;font-family:ArialMT_k0;color:#000;}
.sb_113{font-size:14px;font-family:ArialMT_5tg;color:#000;}
.sc_113{font-size:17px;font-family:Webdings_k6;color:#000;}
.sd_113{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.se_113{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.sf_113{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts113" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

@font-face {
	font-family: Webdings_k6;
	src: url("fonts/Webdings_k6.woff") format("woff");
}

</style>
<div id="pg113Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg113" style="-webkit-user-select: none;"><object width="1210" height="935" data="113/113.svg" type="image/svg+xml" id="pdf113" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_113" class="t s0_113">NCCN Guidelines Version 4.2024 </span>
<span id="t2_113" class="t s0_113">Head and Neck Cancers </span>
<span id="t3_113" class="t s1_113">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t4_113" class="t s2_113">® </span>
<span id="t5_113" class="t s1_113">(NCCN </span>
<span id="t6_113" class="t s2_113">® </span>
<span id="t7_113" class="t s1_113">), All rights reserved. NCCN Guidelines </span>
<span id="t8_113" class="t s2_113">® </span>
<span id="t9_113" class="t s1_113">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="ta_113" class="t s3_113">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="tb_113" class="t s3_113">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="tc_113" class="t s4_113">NCCN Guidelines Index </span>
<span id="td_113" class="t s4_113">Table of Contents </span>
<span id="te_113" class="t s4_113">Discussion </span>
<span id="tf_113" class="t s5_113">SYST-A </span>
<span id="tg_113" class="t s5_113">2 OF 4 </span>
<span id="th_113" class="t s6_113">References </span>
<span id="ti_113" class="t s5_113">Recurrent, Unresectable, or Metastatic Disease (with no surgery or RT option) </span>
<span id="tj_113" class="t s5_113">Preferred Regimens </span><span id="tk_113" class="t s5_113">Other Recommended Regimens </span>
<span id="tl_113" class="t s7_113">(First- and Subsequent-Line) </span>
<span id="tm_113" class="t s5_113">Useful in Certain Circumstances </span>
<span id="tn_113" class="t s7_113">(First- and Subsequent-Line) </span>
<span id="to_113" class="t s5_113">First-Line </span>
<span id="tp_113" class="t s8_113">c </span>
<span id="tq_113" class="t s9_113">• </span><span id="tr_113" class="t sa_113">Pembrolizumab/platinum (cisplatin or </span>
<span id="ts_113" class="t s9_113">carboplatin)/5-FU </span><span id="tt_113" class="t s9_113">(category 1) </span>
<span id="tu_113" class="t sb_113">c,32 </span>
<span id="tv_113" class="t s9_113">• </span><span id="tw_113" class="t sa_113">Pembrolizumab (for tumors that </span>
<span id="tx_113" class="t sa_113">express PD-L1 with CPS ≥1) </span>
<span id="ty_113" class="t sb_113">c,32 </span>
<span id="tz_113" class="t s9_113">(category 1) </span>
<span id="t10_113" class="t s7_113">Subsequent-Line (if not previously used) </span>
<span id="t11_113" class="t s9_113">• Nivolumab </span>
<span id="t12_113" class="t sb_113">33 </span>
<span id="t13_113" class="t s9_113">(if disease progression on or </span>
<span id="t14_113" class="t s9_113">after platinum therapy) (category 1) </span>
<span id="t15_113" class="t s9_113">• </span><span id="t16_113" class="t sa_113">Pembrolizumab </span>
<span id="t17_113" class="t sb_113">34-36 </span>
<span id="t18_113" class="t s9_113">(if disease progression </span>
<span id="t19_113" class="t s9_113">on or after platinum therapy) (category 1) </span>
<span id="t1a_113" class="t s5_113">Combination Regimens </span>
<span id="t1b_113" class="t s9_113">• Cetuximab/platinum (cisplatin or </span>
<span id="t1c_113" class="t s9_113">carboplatin)/5-FU </span>
<span id="t1d_113" class="t sb_113">37 </span>
<span id="t1e_113" class="t s9_113">(category 1) </span>
<span id="t1f_113" class="t s9_113">• Cisplatin/cetuximab </span>
<span id="t1g_113" class="t sb_113">38 </span>
<span id="t1h_113" class="t s9_113">• Cisplatin or carboplatin/docetaxel </span>
<span id="t1i_113" class="t sb_113">39 </span>
<span id="t1j_113" class="t s9_113">or paclitaxel </span>
<span id="t1k_113" class="t sb_113">40 </span>
<span id="t1l_113" class="t s9_113">• Cisplatin/5-FU </span>
<span id="t1m_113" class="t sb_113">40,41 </span>
<span id="t1n_113" class="t s9_113">• Cisplatin or carboplatin/docetaxel/cetuximab </span>
<span id="t1o_113" class="t sb_113">42 </span>
<span id="t1p_113" class="t s9_113">• Cisplatin or carboplatin/paclitaxel/cetuximab </span>
<span id="t1q_113" class="t sb_113">43 </span>
<span id="t1r_113" class="t s9_113">• </span><span id="t1s_113" class="t sa_113">Pembrolizumab/platinum (cisplatin or carboplatin)/ </span>
<span id="t1t_113" class="t s9_113">docetaxel </span>
<span id="t1u_113" class="t sb_113">32,39 </span>
<span id="t1v_113" class="t s9_113">• </span><span id="t1w_113" class="t sa_113">Pembrolizumab/platinum (cisplatin or carboplatin)/ </span>
<span id="t1x_113" class="t s9_113">paclitaxel </span>
<span id="t1y_113" class="t sb_113">32,40,44 </span>
<span id="t1z_113" class="t s5_113">Single Agents </span>
<span id="t20_113" class="t s9_113">• Cisplatin </span>
<span id="t21_113" class="t sb_113">38,45 </span>
<span id="t22_113" class="t s9_113">• Carboplatin </span>
<span id="t23_113" class="t sb_113">46 </span>
<span id="t24_113" class="t s9_113">• Paclitaxel </span>
<span id="t25_113" class="t sb_113">47 </span>
<span id="t26_113" class="t s9_113">• Docetaxel </span>
<span id="t27_113" class="t sb_113">48,49 </span>
<span id="t28_113" class="t s9_113">• 5-FU </span>
<span id="t29_113" class="t sb_113">45 </span>
<span id="t2a_113" class="t s9_113">• Methotrexate </span>
<span id="t2b_113" class="t sb_113">41,50 </span>
<span id="t2c_113" class="t s9_113">• Cetuximab </span>
<span id="t2d_113" class="t sb_113">51,52 </span>
<span id="t2e_113" class="t s9_113">• Capecitabine </span>
<span id="t2f_113" class="t sb_113">53 </span>
<span id="t2g_113" class="t s9_113">• Afatinib </span>
<span id="t2h_113" class="t sb_113">54 </span>
<span id="t2i_113" class="t s9_113">(subsequent-line only, if disease </span>
<span id="t2j_113" class="t s9_113">progression on or after platinum therapy) </span>
<span id="t2k_113" class="t s9_113">(category 2B) </span>
<span id="t2l_113" class="t s9_113">• Squamous cell carcinoma </span>
<span id="t2m_113" class="t sc_113"></span><span id="t2n_113" class="t s9_113">Cetuximab/nivolumab </span>
<span id="t2o_113" class="t sb_113">55 </span>
<span id="t2p_113" class="t sc_113"></span><span id="t2q_113" class="t sa_113">Cetuximab/pembrolizumab </span>
<span id="t2r_113" class="t sb_113">56 </span>
<span id="t2s_113" class="t s9_113">• For select ethmoid/maxillary sinus cancers </span>
<span id="t2t_113" class="t s9_113">(ie, small cell, SNEC, high-grade olfactory </span>
<span id="t2u_113" class="t s9_113">esthesioneuroblastoma, SNUC with </span>
<span id="t2v_113" class="t s9_113">neuroendocrine features): </span>
<span id="t2w_113" class="t sc_113"></span><span id="t2x_113" class="t s9_113">Cisplatin/etoposide or carboplatin/ </span>
<span id="t2y_113" class="t s9_113">etoposide </span>
<span id="t2z_113" class="t sb_113">15 </span>
<span id="t30_113" class="t sc_113"></span><span id="t31_113" class="t s9_113">Cyclophosphamide/doxorubicin/ </span>
<span id="t32_113" class="t s9_113">vincristine (category 2B) </span>
<span id="t33_113" class="t sb_113">16 </span>
<span id="t34_113" class="t s9_113">• Paclitaxel/cetuximab </span>
<span id="t35_113" class="t sb_113">57 </span>
<span id="t36_113" class="t s9_113">• Docetaxel/cetuximab (category 2B) </span>
<span id="t37_113" class="t sb_113">42 </span>
<span id="t38_113" class="t s9_113">• </span><span id="t39_113" class="t sa_113">Pembrolizumab (for MSI-H, dMMR, or TMB-H </span>
<span id="t3a_113" class="t sa_113">[≥10 mut/Mb] tumors) </span>
<span id="t3b_113" class="t sb_113">58 </span>
<span id="t3c_113" class="t s9_113">• Cisplatin/pemetrexed (for PS 0–1) (category </span>
<span id="t3d_113" class="t s9_113">2B) </span>
<span id="t3e_113" class="t sb_113">59 </span>
<span id="t3f_113" class="t s9_113">• Gemcitabine/paclitaxel (category 2B) </span>
<span id="t3g_113" class="t sb_113">60 </span>
<span id="t3h_113" class="t s9_113">• </span><span id="t3i_113" class="t sa_113" data-mappings='[[34,"fi"]]'>Nivolumab/ipilimumab (CPS ≥20 and ﬁrst-line </span>
<span id="t3j_113" class="t s9_113">only) (category 2B) </span>
<span id="t3k_113" class="t sb_113">61 </span>
<span id="t3l_113" class="t s9_113">• </span><span id="t3m_113" class="t sa_113">Fam-trastuzumab deruxtecan-nxki (for </span>
<span id="t3n_113" class="t sa_113">HER2+ (IHC 3+) solid tumors; subsequent </span>
<span id="t3o_113" class="t s9_113">line only with no satisfactory alternative </span>
<span id="t3p_113" class="t s9_113">treatment options) (category 2B) </span>
<span id="t3q_113" class="t sb_113">62 </span>
<span id="t3r_113" class="t s5_113">• The choice of systemic therapy should be individualized based on patient characteristics (eg, PS, goals of therapy). </span>
<span id="t3s_113" class="t sd_113">c </span>
<span id="t3t_113" class="t se_113">If not previously used, these regimens may be considered in subsequent-line therapy as other recommended regimens. </span>
<span id="t3u_113" class="t s5_113">PRINCIPLES OF SYSTEMIC THERAPY FOR NON-NASOPHARYNGEAL CANCERS </span>
<span id="t3v_113" class="t s5_113">(Oral Cavity [including mucosal lip], Oropharynx, Hypopharynx, Glottic Larynx, Supraglottic Larynx, Ethmoid Sinus, Maxillary Sinus, and </span>
<span id="t3w_113" class="t s5_113">Occult Primary) </span>
<span id="t3x_113" class="t sf_113">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
